The FDA is helping Novartis approve Cosentyx.
The FDA approved Cosentyx (secukinumab, Novartis) as the first anti-IL-17 biologic for polymyalgia rheumatica (PMR) based on the Phase III REPLENISH trial, in which the drug nearly doubled the likelihood of sustained remission.
Cosentyx is already one of the most "all-consuming" biological drugs on the market - psoriasis, osteoarthritis, hidradenitis, and now also PMR, a disease that has been treated for decades with banal steroids for three rubles. Novartis is simply finding another indication for a molecule that has already been reduced and given exclusivity for years - classic life cycle management, not innovation.
Why is this important? For older patients with PMR for whom steroids are contraindicated or unresponsive, this is the first targeted alternative. For the health system - another line in the budget for biological treatment instead of cheap prednisolone.
In Kazakhstan they will approve within 15 days.